AzTrials
AzTrials

Mild Traumatic Brain Injury, ConcussionNCT06735157

Repetitive Transcranial Magnetic Stimulation Paired with Augmented Reality to Alter Concussion Symptoms

A study testing Repetitive transcranial magnetic stimulation and Augmented reality vestibular rehabilitation therapy in people with Mild Traumatic Brain Injury, Concussion and Chronic Dizziness, run by McMaster University at 2 sites in Canada.

Not yet recruiting

Opening soon. The study is approved but enrolment has not started yet. Sites may already take enquiries.

Sites and contacts
Official record

Search all trials

Trial summary

This study aims to determine whether the delivery of brain stimulation paired with a balance training task can improve symptoms of dizziness for individuals experiencing these symptoms due to concussion. Read more about this study

Who is it for?
Ages 18 to 65 years
What is being tested?
Repetitive transcranial magnetic stimulation and Augmented reality vestibular rehabilitation therapy
Could I receive a placebo?
Yes, some participants may receive a placebo
How many people
40 participants
Where
2 sitesCanada
Study dates
1 Jan 2025to 1 Dec 2025
Phase
Interventional

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 65 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Male or female aged 18-65 years
  • Diagnosis of mTBI according to the American Congress of Rehabilitation Medicine Diagnostic Criteria (Silverberg et al., 2023). All participants have diagnosis confirmed with Dr. Rathbone before enrollment.
  • Persistent dizziness beyond 3-months following the initial head injury.
  • Comprehension of spoken and written English language or have a language interpreter present for all study visits.

Who cannot join

  • History of chronic dizziness unrelated to concussive events.
  • Contraindications to TMS: presence of pacemaker, metal/electrical/magnetic implants not including titanium, known history of untreated or uncontrolled psychological disorders, pregnancy, history of seizure or diagnoses of epilepsy, taking medications that increase the risk of seizure.
  • Inability to continue current medical therapies for the duration of the study.
  • If imaging was done at the time of injury, individuals with a positive CT head will be excluded from the study

Trial locations and contacts

2 sites in 1 country. Contact the study team or a site near you to ask about taking part.

Daniel B Soppitt, BSc contact

9052463301

soppittd@mcmaster.ca

Canada2 sites
  • Greenbank Concussion Clinic

    Hamilton, Ontario, L8N 2B6

    Michel Rathbone, MB, Ch.B., PhD, FRCP(C), (905) 574-8630, mrathbon@mcmaster.ca

  • McMaster University

    Hamilton, Ontario, L8S 4L8

    Aimee J. Nelson, PhD, 9055259140 ext. 28053, nelsonaj@mcmaster.ca

    Daniel B. Soppitt, BSc

Other trials in Canada

About this study

This study aims to determine whether the delivery of brain stimulation paired with a balance training task can improve symptoms of dizziness for individuals experiencing these symptoms due to concussion. The main questions it aims to answer are:

  • Does repetitive transcranial magnetic stimulation (rTMS) paired with balance training improve the symptoms of dizziness in individuals with persistent dizziness due to concussion?
  • Is the proposed rTMS and balance training protocol feasible in this population?
Read more

Researchers will compare results from a sham rTMS group with those from a real rTMS group to see if any observed changes are from the placebo effect rather than the expected effects of real rTMS.

Participants will receive pulses of rTMS to the area of the brain responsible for control of movement and then be asked to interact with digital objects using augmented reality glasses for 14 days over 3 weeks.

Read the detailed description

The incidence of traumatic brain injury (TBI) is increasing in Canada, and it is expected to be one of the most common neurological conditions affecting Canadians by 2031. Up to 90% of TBIs are classified as mild (m)TBI, also known as concussion. A federal concussion report from 2019 indicated an annual prevalence of 200,000 mTBIs in Canada. Symptoms of mTBI, termed post-concussion symptoms (PCS), include dizziness, headache, alterations in mood, and cognitive impairment. PCS generally resolves on its own. However, some patients experience persistent PCS lasting beyond 3 months after the initial head injury.

Dizziness is the second most common symptom of mTBI after headache. It is estimated that up to 81% of mTBI patients will present with dizziness upon initial clinical examination, which may continue to persist beyond 1-year following the initial trauma in 25% of patients. Post-concussion dizziness (PCD) can present as postural instability, ongoing vertigo, balance impairments, nausea, and intolerance to head motion. These symptoms can drastically reduce quality of life and impact the ability to drive, work, and perform daily activities.

PCD is typically associated with vestibular impairment. Further, many patients complaining of dizziness following mTBI demonstrate physiologic abnormalities with the auditory and vestibular systems. Consequently, the most preferable treatment for PCD is a form of balance training called vestibular rehabilitation therapy (VRT). VRT consists of a set of exercises which promote adaptation, substitution, and habituation of the vestibular system. Adaptation, mediated by neuroplasticity, is the gradual remodelling of the nervous system as it "adapts" to the signals from the damaged vestibular system. Substitution is the process of learning strategies to compensate for poor vestibular function. Habituation is the gradual desensitization to certain movements through repeated exposure to those movements. These exercises are often individually prescribed based on personal areas of disability. Specific exercise types include gaze stability, habituation, substitution, and balance exercises. These target deficits in the vestibulo-ocular reflex (VOR), improve impaired motion sensitivity, facilitate central reprogramming, and improve balance. Traditional VRT, such as a balance task, is monotonous and often requires trained professionals to administer. VRT, in the form of interactive games, however, is engaging and has been shown to affect balance, dizziness, and mobility positively. A form of sensorimotor training consisting of an interactive game presented through augmented reality (AR) has not yet been explored. It may serve to reduce PCD by similar mechanisms as the aforementioned VRTs.

AR is typically presented through opaque glasses, which overlay virtual objects onto the user's environment. Users can then interact with both the virtual and physical environments simultaneously. Our AR intervention involves a game that promotes goal-directed movements of the head to accomplish tasks in various head orientations and postural positions. Through repeated exposure, this game aims to facilitate adaptation, substitution, and habituation of the vestibular system to reduce PCD.

A non-invasive neuromodulation technique called repetitive transcranial magnetic stimulation (rTMS) may improve AR vestibular training. One form of rTMS delivery called intermittent theta burst stimulation (iTBS) promotes synaptic plasticity by inducing long term potentiation (LTP)-like changes in neuronal excitability. Literature suggests that iTBS delivered to the primary motor cortex (M1) may improve learning in conjunction with motor training. rTMS may also improve dizziness. Ten sessions of rTMS reduce dizziness symptom severity and frequency by more than 50% in patients suffering from severe PCD. iTBS delivered to M1 improves balance in post-stroke patients. Systemic inflammation is an important physiological response to mTBI that may contribute to dizziness. Several studies have observed the anti-inflammatory effects of rTMS in clinical populations such as stroke and depression. Zhao et al. found that 20 sessions of rTMS on patients with refractory depression reduced elevated levels of TNF-⍺ and IL-1β to that of healthy controls. Levels of BDNF, which is important for brain growth, increased to that of healthy controls following the intervention. This effect on TNF-⍺, IL-1β, and BDNF was not observed in the clinical control group who did not receive rTMS. Cha et al. reported a similar reduction in inflammatory cytokines TNF-⍺, IL-1β, and IL-6 after 10 sessions of rTMS in post-stroke patients. Velioglu et al. found that 10 sessions of rTMS increased BDNF in patients with Alzheimer's disease. These effects also provide evidence towards a possible mechanism behind the effect of rTMS on other persistent PCS.

Patients with severe persistent PCD often require medical or surgical intervention. There is a clear need for non-invasive treatment options for these individuals. The primary objective of this study is to determine if the proposed technique is feasible and can be used to alter concussion symptoms in patients with PCD in a larger study. This study will also explore the effects of iTBS in combination with AR vestibular training on dizziness disability and postural stability in patients with PCD. Additionally, this research aims to determine if rTMS can modulate inflammation in persistent PCS.

Being tested
Repetitive transcranial magnetic stimulation, Augmented reality vestibular rehabilitation therapy, SHAM repetitive transcranial magnetic stimulation
Keywords
Concussion, Dizziness, Transcranial magnetic stimulation, augmented reality, repetitive transcranial magnetic stimulation, mild traumatic brain injury, intermittent theta burst stimulation, accelerated iTBS, balance training, vestibular rehabilitation therapy
Medical subject headings
Brain Concussion, Vestibular Diseases, Dizziness

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Repetitive transcranial magnetic stimulationDevice

    Also called Intermittent theta burst stimulation

    Repetitive transcranial magnetic stimulation (intermittent theta burst stimulation) will be delivered using a Magstim Rapid 2 stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby iTBS will be delivered three times during the same study session. Each iTBS session will deliver 600 pulses in 50 Hz bursts of 3 pulses for a total of 1800 pulses delivered each day. iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.

  • Augmented reality vestibular rehabilitation therapyBehavioural

    Also called Vestibular rehabilitation therapy, Balance training, Vestibular training, Augmented reality

    Participants will complete the vestibular training through Nreal Air AR Glasses (Nreal, China). The vestibular training task was custom-made in Unity V2021.3.14fI software using C+ script language. Participants will be standing upright for the AR training, with a safety bar positioned directly in front of them should they need to hold onto something. A large cross-shaped target will be positioned approximately 3 feet in front of the participant's head with its vertical center aligned with the participant's midline. This will act as a visual starting point. The training is adapted from clinical vestibular rehabilitation training methods used in PCD. The vestibular training task consists of locating and tracking a series of moving 3-dimensional balls presented at random within the participant's field of view.

  • SHAM repetitive transcranial magnetic stimulationDevice

    Also called Sham intermittent theta burst stimulation

    Sham repetitive transcranial magnetic stimulation will be delivered using a Magstim Rapid 2 sham stimulator (Magstim, Whitland, UK) guided using neuronavigation (Brainsight, Rogue Research, Montreal, QC, Canada) to target primary motor cortex. Participants will receive 14 days of sham stimulation over a 3-week period. Stimulation will use a protocol called accelerated iTBS (Duprat et al., 2016) whereby sham iTBS will be delivered three times during the same study session. Each sham iTBS session will sound and feel identical to real iTBS delivery, but will not deliver a stimulating current. Sham iTBS sessions will each be separated by 15 minutes (Duprat et al., 2016; Wu et al., 2013). Sham stimulation will be delivered at 70% of the participant's resting motor threshold. Immediately following each 600-pulse period of sham iTBS, individuals will participate in 5 to 10 minutes of AR vestibular rehabilitation therapy.

Study groups in NCT06735157
Study groupRoleWhat they receive
Sham rTMSSham comparatorNot described
Receives: Behavioral: Augmented reality vestibular rehabilitation therapy; Device: SHAM repetitive transcranial magnetic stimulation
Real rTMSActive comparatorNot described
Receives: Device: Repetitive transcranial magnetic stimulation; Behavioral: Augmented reality vestibular rehabilitation therapy

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Dizziness Handicap Inventory (DHI)

    The DHI is a well-validated 25-item questionnaire which will be used to assess functional, physical, and emotional domains of disability due to dizziness. The test has a total possible score of 100 points, whereby 16-34 = mild handicap, 36-52 = moderate handicap, and 54+ = severe handicap.

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

Secondary outcomes (9)
  1. Balance Error Scoring System (BESS)

    The BESS is an objective and quantitative measure used to assess postural stability deficits in mTBI. The assessment will take place on a force plate (BTrackS; balancetrackingsystems.com) in order to measure the participant's center of gravity and sway. The BESS consists of 3 eyes-closed stances: feet together with hands on the hips, single-leg stance on nondominant foot with hands on the hips, and tandem stance with nondominant foot behind the dominant foot. The dominant foot will be identified by determining which foot is used to kick a ball. Each stance is performed on a stable surface (hard floor) and an unstable surface (foam pad) with the eyes closed for 20-seconds per trial. Errors are counted during each trial. BESS results will be reported as a score from 0 to 60, with higher scores representing greater deficits in postural stability (worse outcome).

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

  2. Activities-Specific Balance Confidence (ABC) Scale

    This questionnaire will be used to evaluate participants' balance confidence. An average of balance confidence as it relates to 16 specific everyday activities will be reported from 0% (no confidence) to 100% (complete confidence).

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

  3. Rivermead Post Concussion Symptoms Questionnaire (RPSQ-3 and RPSQ-13)

    This questionnaire will assess the presence and severity of a wide range of post-concussion symptoms.

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

  4. PROMIS-29

    This questionnaire will assess six domains of health (physical function, anxiety, depression, fatigue, sleep disturbance, social activities) as they relate to participants' dizziness. Questions under the headings "Pain Intensity" and "Pain Interference" will be omitted from this questionnaire as they do not relate to the population.

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

  5. Motor evoked potential (MEP)

    This measure will be used to assess changes in corticospinal excitability. To obtain MEP, thirty individual pulses of TMS at 120% RMT will be applied over the motor hotspot of the dominant hand FDI muscle.

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

  6. Cytokines (IL-1ß, IL-6, TNF-⍺, IL-10)

    A blood sample will be used to evaluate changes in serum concentrations (pg/mL) of cytokines IL-1ß, IL-6, TNF-⍺, IL-10.

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

  7. C-reactive protein

    A blood sample will be used to evaluate changes in serum C-reactive protein concentrations (µg/mL).

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

  8. Monocyte chemoattractant protein-1

    A blood sample will be used to evaluate changes in serum concentrations (pg/mL) of monocyte chemoattractant protein-1.

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

  9. Brain-derived neurotrophic factor

    A blood sample will be used to evaluate changes in serum concentrations (ng/mL) of brain-derived neurotrophic factor.

    Measured: At baseline (before the first intervention session) and post-intervention (following the final intervention session)

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted16 Dec 2024
  2. Study start1 Jan 2025 (estimated)
  3. Primary completion1 Dec 2025 (estimated)
  4. Study completion1 Dec 2025 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Model description
Participants will be split into two groups, one that will receive real rTMS and one that will receive sham rTMS.
Masking
Single blind
Who is masked
Participant
Enrolment
40 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT06735157
Sponsor's protocol ID
17699
Status last verified
Dec 2024
First submitted
10 Dec 2024
Last updated
13 Jan 2025
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Publications

  • Zhao X, Li Y, Tian Q, Zhu B, Zhao Z. Repetitive transcranial magnetic stimulation increases serum brain-derived neurotrophic factor and decreases interleukin-1beta and tumor necrosis factor-alpha in elderly patients with refractory depression. J Int Med Res. 2019 May;47(5):1848-1855. doi: 10.1177/0300060518817417. Epub 2019 Jan 7.

    PubMed 30616482
  • Zuo C, Cao H, Feng F, Li G, Huang Y, Zhu L, Gu Z, Yang Y, Chen J, Jiang Y, Wang F. Repetitive transcranial magnetic stimulation exerts anti-inflammatory effects via modulating glial activation in mice with chronic unpredictable mild stress-induced depression. Int Immunopharmacol. 2022 Aug;109:108788. doi: 10.1016/j.intimp.2022.108788. Epub 2022 Apr 30.

    PubMed 35504201
  • Velioglu HA, Hanoglu L, Bayraktaroglu Z, Toprak G, Guler EM, Bektay MY, Mutlu-Burnaz O, Yulug B. Left lateral parietal rTMS improves cognition and modulates resting brain connectivity in patients with Alzheimer's disease: Possible role of BDNF and oxidative stress. Neurobiol Learn Mem. 2021 Apr;180:107410. doi: 10.1016/j.nlm.2021.107410. Epub 2021 Feb 18.

    PubMed 33610772
  • Rajkumar RP. Immune-inflammatory markers of response to repetitive transcranial magnetic stimulation in depression: A scoping review. Asian J Psychiatr. 2024 Jan;91:103852. doi: 10.1016/j.ajp.2023.103852. Epub 2023 Nov 29.

    PubMed 38070319
  • Cha B, Kim J, Kim JM, Choi JW, Choi J, Kim K, Cha J, Kim M. Therapeutic Effect of Repetitive Transcranial Magnetic Stimulation for Post-stroke Vascular Cognitive Impairment: A Prospective Pilot Study. Front Neurol. 2022 Mar 22;13:813597. doi: 10.3389/fneur.2022.813597. eCollection 2022.

    PubMed 35392634
  • Visser K, Koggel M, Blaauw J, van der Horn HJ, Jacobs B, van der Naalt J. Blood-based biomarkers of inflammation in mild traumatic brain injury: A systematic review. Neurosci Biobehav Rev. 2022 Jan;132:154-168. doi: 10.1016/j.neubiorev.2021.11.036. Epub 2021 Nov 23.

    PubMed 34826510
  • Liao LY, Zhu Y, Peng QY, Gao Q, Liu L, Wang QH, Gao SH, Tao Y, Huang H, Xu PD, Gao CY. Intermittent Theta-Burst Stimulation for Stroke: Primary Motor Cortex Versus Cerebellar Stimulation: A Randomized Sham-Controlled Trial. Stroke. 2024 Jan;55(1):156-165. doi: 10.1161/STROKEAHA.123.044892. Epub 2023 Nov 30.

    PubMed 38037225
  • Paxman E, Stilling J, Mercier L, Debert CT. Repetitive transcranial magnetic stimulation (rTMS) as a treatment for chronic dizziness following mild traumatic brain injury. BMJ Case Rep. 2018 Nov 5;2018:bcr2018226698. doi: 10.1136/bcr-2018-226698.

    PubMed 30396889
  • Zhang JJ, Bai Z, Fong KNK. Priming Intermittent Theta Burst Stimulation for Hemiparetic Upper Limb After Stroke: A Randomized Controlled Trial. Stroke. 2022 Jul;53(7):2171-2181. doi: 10.1161/STROKEAHA.121.037870. Epub 2022 Mar 23.

    PubMed 35317611
  • Platz T, Adler-Wiebe M, Roschka S, Lotze M. Enhancement of motor learning by focal intermittent theta burst stimulation (iTBS) of either the primary motor (M1) or somatosensory area (S1) in healthy human subjects. Restor Neurol Neurosci. 2018;36(1):117-130. doi: 10.3233/RNN-170774.

    PubMed 29439364
  • Huang YZ, Sommer M, Thickbroom G, Hamada M, Pascual-Leonne A, Paulus W, Classen J, Peterchev AV, Zangen A, Ugawa Y. Consensus: New methodologies for brain stimulation. Brain Stimul. 2009 Jan;2(1):2-13. doi: 10.1016/j.brs.2008.09.007. Epub 2008 Oct 7.

    PubMed 20633398
  • Szturm T, Betker AL, Moussavi Z, Desai A, Goodman V. Effects of an interactive computer game exercise regimen on balance impairment in frail community-dwelling older adults: a randomized controlled trial. Phys Ther. 2011 Oct;91(10):1449-62. doi: 10.2522/ptj.20090205. Epub 2011 Jul 28.

    PubMed 21799138
  • Rosiak O, Krajewski K, Woszczak M, Jozefowicz-Korczynska M. Evaluation of the effectiveness of a Virtual Reality-based exercise program for Unilateral Peripheral Vestibular Deficit. J Vestib Res. 2018;28(5-6):409-415. doi: 10.3233/VES-180647.

    PubMed 30714985
  • Smolka W, Smolka K, Markowski J, Pilch J, Piotrowska-Seweryn A, Zwierzchowska A. The efficacy of vestibular rehabilitation in patients with chronic unilateral vestibular dysfunction. Int J Occup Med Environ Health. 2020 Apr 30;33(3):273-282. doi: 10.13075/ijomeh.1896.01330. Epub 2020 Mar 26.

    PubMed 32235946
  • Aligene K, Lin E. Vestibular and balance treatment of the concussed athlete. NeuroRehabilitation. 2013;32(3):543-53. doi: 10.3233/NRE-130876.

    PubMed 23648608

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in